Sales Growth YoY (Last 12 Months): Iovance Biotherapeutics (IOVA)

The 12-month year-over-year revenue growth rate illustrates the dynamics of Iovance Biotherapeutics (IOVA), where the 51.60 mark serves as a key metric. Growth is driven by the scaling of the clinic network to reduce costs. Stability of output is guaranteed by its own sterile manufacturing plant in Philadelphia, while a focus on innovation is maintained by outsourcing logistics and testing to external contractors.
Iovance Biotherapeutics, Inc. (IOVA) - metric breakdowns and financial figures

This indicator tracks business expansion rates by comparing total revenue over the last 12 months with the same period last year to eliminate quarterly gaps. By analyzing the trajectory of the 12-month annual revenue change, an investor assesses the commercialization of TIL therapy by Iovance Biotherapeutics (IOVA), where a sharp increase in the metric confirms the successful market launch of a unique treatment method for advanced melanoma.